Ferring Favorite To Get First Approval For Microbiota-Based Therapy

08 Jul 2019

If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.

Race — Ferring ahead of the field for microbiome-based therapies • Source: Shutterstock

Ferring Pharmaceuticals AS is in pole position to be first pharmaceutical company to file a treatment that harnesses the power of the human microbiome, with a potential launch pencilled in next year for RBX2660 for reducing recurrent Clostridioides difficile (C diff) infection in adults.

The privately owned Swiss firm, best known for its reproductive medicines, has made the microbiome a key element of its growth strategy especially since the acquisition last year of the US firm Rebiotix Inc.. The latter, founded in 2011, processes stool donations using its MRT drug platform to deliver healthy, live, human-derived microbes into C diff patients' intestinal tracks

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

23 Apr 2025

• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

25 Mar 2025

• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

Profile: Anil Koul’s Journey From ‘Jumping Genes’ To Sirturo And AI-Led Drug Discovery

24 Mar 2025

• By Anju Ghangurde

Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.

Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy

13 Mar 2025

• By Alaric DeArment

The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.